Cargando…

Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma

Testing of the MGMT promoter methylation status in glioblastoma is relevant for clinical decision making and research applications. Two recent and independent phase III therapy trials confirmed a prognostic and predictive value of the MGMT promoter methylation status in elderly glioblastoma patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Preusser, Matthias, Berghoff, Anna S., Manzl, Claudia, Filipits, Martin, Weinhäusel, Andreas, Pulverer, Walter, Dieckmann, Karin, Widhalm, Georg, Wöhrer, Adelheid, Knosp, Engelbert, Marosi, Christine, Hainfellner, Johannes A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dustri-Verlag Dr. Karl Feistle 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891253/ https://www.ncbi.nlm.nih.gov/pubmed/24359605 http://dx.doi.org/10.5414/NP300730

Ejemplares similares

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions
por: Bienkowski, Michal, et al.
Publicado: (2015)

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas
por: Micko, Alexander S. G., et al.
Publicado: (2017)

MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals
por: Micko, Alexander S. G., et al.
Publicado: (2018)

Clinical neuropathology practice guide 1-2013: Molecular subtyping of glioblastoma: ready for clinical use?
por: Woehrer, Adelheid, et al.
Publicado: (2013)

Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how?
por: Berghoff, Anna S., et al.
Publicado: (2012)

Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers
por: Berghoff, Anna S., et al.
Publicado: (2013)

5-Aminolevulinic Acid Induced Fluorescence Is a Powerful Intraoperative Marker for Precise Histopathological Grading of Gliomas with Non-Significant Contrast-Enhancement
por: Widhalm, Georg, et al.
Publicado: (2013)

Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma
por: Mair, Maximilian J., et al.
Publicado: (2020)

Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status
por: Grabner, Günther, et al.
Publicado: (2016)

Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
por: Mair, Maximilian J., et al.
Publicado: (2021)

LAG-3 expression in the inflammatory microenvironment of glioma
por: Mair, Maximilian J., et al.
Publicado: (2021)

Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas
por: Haberler, Christine, et al.
Publicado: (2014)

Response to imatinib as a function of target kinase expression in recurrent glioblastoma
por: Hassler, Marco Ronald, et al.
Publicado: (2014)

SURG-13. EVALUATION OF 5-ALA FLUORESCENCE IN BRAIN METASTASES OF VARIOUS PRIMARY TUMORS: A MULTICENTER STUDY WITH EXPERIENCE IN 157 CASES
por: Mercea, Petra Andreea, et al.
Publicado: (2019)

Noninvasive Differentiation of Meningiomas and Dural Metastases Using Intratumoral Vascularity Obtained by Arterial Spin Labeling
por: Furtner, Julia, et al.
Publicado: (2019)

Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers
por: Berghoff, Anna Sophie, et al.
Publicado: (2012)

Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
por: Preusser, Matthias, et al.
Publicado: (2015)

Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours
por: Mair, Maximilian J, et al.
Publicado: (2020)

Clinical neuropathology practice news 2-2012: BRAF V600E testing
por: Capper, David, et al.
Publicado: (2012)

Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times
por: Berghoff, Anna Sophie, et al.
Publicado: (2013)

Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center
por: Füreder, L. M., et al.
Publicado: (2018)

Enhanced expression of autophagy‐related p62 without increased deposits of neurodegeneration‐associated proteins in glioblastoma and surrounding tissue – An autopsy‐based study
por: Klotz, Sigrid, et al.
Publicado: (2022)

Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors
por: Berghoff, A S, et al.
Publicado: (2012)

Prognostic impact of genetic alterations and methylation classes in meningioma
por: Berghoff, Anna S., et al.
Publicado: (2022)

Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
por: Berghoff, Anna S, et al.
Publicado: (2016)

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
por: Håvik, Annette Bentsen, et al.
Publicado: (2012)

Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastoma
por: Li, Mingxiao, et al.
Publicado: (2021)

Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer
por: Wolff, Ladislaia, et al.
Publicado: (2023)

Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients
por: Quillien, Véronique, et al.
Publicado: (2014)

Prognostic Role of Methylation Status of the MGMT Promoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients
por: Kim, Dae Cheol, et al.
Publicado: (2016)

The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma
por: Villani, Veronica, et al.
Publicado: (2015)

Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases
por: Steindl, A., et al.
Publicado: (2021)

Patterns of diagnostic marker assessment in adult diffuse glioma: a survey of the European Confederation of Neuropathological Societies (Euro-CNS)
por: Woehrer, Adelheid, et al.
Publicado: (2017)

Frequent MGMT (0(6)-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience
por: Baur, Martina, et al.
Publicado: (2010)

Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial
por: Quillien, Véronique, et al.
Publicado: (2016)

MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response
por: Switzeny, Olivier J., et al.
Publicado: (2016)

The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients’ survival: a meta-analysis
por: Zhao, Hailong, et al.
Publicado: (2016)

Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients
por: Estival, Anna, et al.
Publicado: (2019)

Clinical Neuropathology image 5-2016: neurofibrillary tangle-rich ganglioglioma
por: Gelpi, Ellen, et al.
Publicado: (2016)

Clinical Neuropathology teaching case 4-2015: Heterogenous brain pathologies temporally and spatially coinciding in limbic regions
por: Kovacs, Gabor G., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_set8163g55f3op1oohes7d603p